Literature DB >> 32032019

Rifampicin resistant tuberculosis in presumptive pulmonary tuberculosis cases in Dubti Hospital, Afar, Ethiopia.

Gebremedhin Bizayene Gebrehiwet1, Atsebeha Gebrekidan Kahsay2, Letmichael Negash Welekidan3, Amlsha Kahsay Hagos4, Getahun Kahsay Abay5, Dawit Gebreegziabiher Hagos6.   

Abstract

INTRODUCTION: Ethiopia stood third in drug-resistant tuberculosis (TB) in Africa, and more than 5,000 MDR-TB patients are reported each year. Greater than 90% of rifampicin (RIF) resistant strains are resistant to isoniazid (INH) and hence the objective of this study was to determine the prevalence and risk factors of RIF resistant MTB among presumptive TB cases at Dubti General Hospital, Afar, Ethiopia.
METHODOLOGY: In this cross-sectional study, 384 presumptive TB cases were recruited and a structured questionnaire was used to collect socio-demographic and clinical data. Sputum samples were collected and examined using X-pertMTB/RIF assay. Bivariate, multivariate logistic regressions, and fishers' exact analysis were done to assess the associations between the prevalence of TB and MDR-TB with different socio-demographic and clinical variables.
RESULTS: In the present study, the overall prevalence of pulmonary TB was 24.5% (94/384), of this 4 (4.3%) isolates were resistant to RIF. History of anti-TB treatment (AOR = 2.4, 95% CI: 1.3-4.4 and TB contact (AOR = 3.6, 95% CI: 2.1-6.2 were significantly associated with gene X-pert MTB/RIF positive TB. Moreover, resistance to rifampicin was statistically associated with the history of TB contact with multi-drug resistant TB (P = 0.027) and khat chewer cases (P = 0.04).
CONCLUSIONS: The overall prevalence of TB and its drug-resistant were relatively higher than that of in the general population in Ethiopia. History of anti-TB treatment and TB contact were significantly associated with X-pert MTB/RIF positive MDR-TB. Copyright (c) 2019 Gebremedhin Bizayene Gebrehiwet, Atsebeha Gebrekidan Kahsay, Letmichael Negash Welekidan, Amlsha Kahsay Hagos, Getahun Kahsay Abay, Dawit Gebreegziabiher Hagos.

Entities:  

Keywords:  Presumptive TB; RIF resistant MTB; Risk factors

Mesh:

Substances:

Year:  2019        PMID: 32032019     DOI: 10.3855/jidc.10462

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  5 in total

1.  Trends of Mycobacterium tuberculosis and rifampicin resistance in Adigrat General Hospital, Eastern zone of Tigrai, North Ethiopia.

Authors:  Getachew Kahsu Abay; Bahlbi Hailay Abraha
Journal:  Trop Dis Travel Med Vaccines       Date:  2020-08-28

2.  Rifampicin-Resistant Mycobacterium tuberculosis Among Patients with Presumptive Tuberculosis in Addis Ababa, Ethiopia.

Authors:  Shambel Araya; Abebe Edao Negesso; Zemenu Tamir
Journal:  Infect Drug Resist       Date:  2020-10-06       Impact factor: 4.003

3.  Differential yield of universal versus selective drug susceptibility testing of patients with tuberculosis in high-burden countries: a systematic review and meta-analysis.

Authors:  Anita Svadzian; Giorgia Sulis; Genevieve Gore; Madhukar Pai; Claudia M Denkinger
Journal:  BMJ Glob Health       Date:  2020-10

4.  Magnitude of Mycobacterium tuberculosis Infection and Its Resistance to Rifampicin Using Xpert-MTB/RIF Assay Among Presumptive Tuberculosis Patients at Motta General Hospital, Northwest Ethiopia.

Authors:  Tesfaye Andualem Demissie; Dereje Belayneh
Journal:  Infect Drug Resist       Date:  2021-04-07       Impact factor: 4.003

5.  Rifampicin resistance in Mycobacterium tuberculosis in Iran: a two-centre study.

Authors:  F Bahraminia; M Zangiabadian; M J Nasiri; M Fattahi; M Goudarzi; R Ranjbar; A A Imani Fooladi
Journal:  New Microbes New Infect       Date:  2021-06-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.